Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Pharmaceuticals  // Browsing posts in Pharmaceuticals

Biosimilars Whisper

Biosimilars Whisper

Research Question: Will Novartis’ Sandoz Zarxio, the first biosimilar approved by the U.S. FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilar drugs? Companies Covered: Amgen (AMGN), Novartis AG (NVS), Hospera (HSP), Celltrion (068270.KQ), Merck (MRK), Express Scripts (ESRX) Report Available: May 21, 2015   Blueshift’s […]

Read more...

Teva’s Long-Term Success Will Depend on Strategic Acquisitions

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies: ACT, AZN, BIIB, HSP, MYL, NVS, PFE, SLXP, TSE:VRX, TLV:TEVA By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Ten sources who commented offered mixed responses on the likelihood of Teva Pharmaceutical Industries […]

Read more...

Teva Pharmaceuticals Whisper

Teva Pharmaceuticals Whisper

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies Covered: Teva Pharmaceuticals (TEVA), Novartis AG (NVS), Mylan (MYL) Report Available: March 25, 2015   Blueshift’s initial research shows Teva’s highly profitable MS drug, Copaxone, is nearing the patent cliff, though its patent-protected reformulation of […]

Read more...

Current Exparel Users Satisfied; FDA Concerns Create Potential Hurdles

Research Question: Has the FDA warning letter negatively affected use of Pacira Pharmaceutical’s Exparel? Companies: HCA, HYH, PCRX By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Two distinct schools of thought on the impact of a September FDA warning letter to Pacira Pharmaceuticals Inc. (PCRX) emerged in this report. Industry specialists […]

Read more...

Pacira Pharmaceuticals

Pacira Pharmaceuticals

Research Question: Has the FDA warning letter negatively impacted Pacira Pharmaceutical’s Exparel use? Companies Covered: Pacira Pharmaceuticals (PCRX) Report Available: Nov. 26, 2014   Blueshift’s initial research shows the FDA warning letter may be hampering Exparel use while the company awaits FDA approval for a nerve block indication.   Observations PCRX is a specialty pharmaceutical […]

Read more...

Market Conditions Prime for More Generic-Drug Price Increases

Research Question: Will declining competition and supply shortages in the generic drug segment continue to drive up prices, or will third-party payers, the FDA and Congress intervene? Companies: ABC, ACT, CAH, CVS, IPXL, LCI, MCK, MYL, RAD, TLV:TEVA, TSE:ENL, WAG, WMT By: David Franklin Click here to download the report (.pdf)   Summary of Findings The trend […]

Read more...

Generic Drug Pricing Whisper

Generic Drug Pricing Whisper

Research Question: Will declining competition and shortages in the generic drug segment continue to drive up prices, or will third-party payers, the FDA, and congress intervene? Companies Covered: Endo International plc (ENDP), Lannett Company, Inc. (LCI), Mylan Inc. (MYL), Actavis PLC (ACT) and Teva Pharmaceutical Industries Ltd. (TLV:TEVA/TEVA) Report Available: October 3, 2014   Blueshift’s initial research shows generic […]

Read more...

Aegerion Pharmaceuticals Whisper

Aegerion Pharmaceuticals Whisper

Research Question: Is the leveling off of Aegerion’s Juxtapid sales permanent or will sales growth return? Companies Covered: Aegerion Pharmaceuticals (AEGR), Isis Pharmaceuticals, Inc. (ISIS), Sanofi (SNY) Report Available: July 16, 2014   Blueshift’s initial research reveals Juxtapid sales slowing, possibly due to a smaller-than-expected patient population and cheaper alternatives, though the company received praise for […]

Read more...

Generic Drug Joint Purchasing Will Squeeze Manufacturers

Research Question: Will joint drug-purchasing agreements made by the largest pharmaceutical retailers and distributors achieve generic-drug price reductions? How will the generic drug channel be affected? Companies: ABC, ACT, BOM:500359, BOM:524715, CAH, COST, CVS, ESRX, KR, MCK, MYL, NVS, RAD, SWY, TLV:TEVA/TEVA, TSE:CTT, WAG, WMT By: David Franklin Click here to download the report (.pdf)   Summary of Findings […]

Read more...

Generic Drug Whisper

Generic Drug Whisper

Research Question: Will the recent joint drug-purchasing agreements by the largest pharmaceutical retailers and distributors achieve anticipated generic drug price reductions, and how will the generic drug channel be impacted? Companies Covered: Actavis (ACT) AmerisourceBergen (ABC), Cardinal Health (CAH), Celesio (CLSI.HM), CVS Caremark (CVS), Express Scripts (ESRX), Hospira (HSP), McKesson, (MCK), Mylan, (MYL), Novartis (NVS), Rite Aid (RAD), Teva […]

Read more...